Kyverna Therapeutics Inc (KYTX)

$4.07 +0.25 (6.54%)
Market Cap 189.95M
Revenue (ttm) 0.00
Net Income (ttm) -127.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 551,011
Avg Vol 509,096
Day's Range N/A - N/A
Shares Out 43.22M
Stochastic %K 67%
Beta 2.95
Analysts Strong Sell
Price Target $17.20

Company Profile

Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-...

Industry: Biotechnology
Sector: Healthcare
Phone: (510) 925-2492
Address:
5980 Horton Street, Suite 550, Emeryville, United States
rsm14il
rsm14il Jul. 16 at 4:51 PM
$ABVX $SLDB $KYTX $UVIX seems like no one is following Abivax. I feel like a small cap foster parent
1 · Reply
mmtiddy
mmtiddy Jul. 16 at 3:58 PM
$KYTX Something is brewing here
0 · Reply
blocktrade
blocktrade Jul. 16 at 2:24 PM
$KYTX weak hands and shorts can 🖕off back over 4🚀
0 · Reply
GSTX7
GSTX7 Jul. 16 at 2:58 AM
$KYTX I traded out on that first dip today. Was up 51% from a couple weeks ago. Second time swing trading with + results. Think the pullback was def sector specific today so I may have left too early. Will hope for another sub-3 entry. Longs are in good shape here. May go long on the next dip if I'm lucky to catch one. Fun stock and a cool company too.
1 · Reply
BluntForceOptions
BluntForceOptions Jul. 15 at 9:40 PM
$KYTX Chart update: We tagged resistance at $4.44 (R-1) before pulling back and closing right at S-1 support ($3.82). After the strong multi-day run from the $2.50 zone, this kind of retracement is normal... even healthy. If we see further downside, I’m watching $3.25 (S-2), which lines up well with the reclaimed trendline that should now serve as support. Still viewing this as digestion, not distribution. Setup’s intact, IMO. Stay tuned.
0 · Reply
ThomasTrainTrader
ThomasTrainTrader Jul. 15 at 7:07 PM
$KYTX healthy pullback for such a huge run, hopefully this stays within the high $3- low $4 range as a temporary floor. This is the most “fair” the valuation has been in ages but it is still an absolute steal below $6, and in a bullish scenario worth close to last years highs around $30
0 · Reply
biospeculator
biospeculator Jul. 15 at 4:38 PM
$KYTX Hopefully a bear raid. Otherwise, pattern has been invalidated. Need this to close above $4.
4 · Reply
blocktrade
blocktrade Jul. 15 at 4:33 PM
$KYTX biotech is getting killed so not surprised considering how much this has moved in the past week.
0 · Reply
AnomalyDetective
AnomalyDetective Jul. 15 at 1:18 PM
As promised, $KYTX first of the Week 29 MDA picks for members up +24.6% from selection in strong breakout conditions with prior Week 28 MDA picks $BTBT +25% $AMPX +51% still going strong at the open today. Simulated weekly MDA portfolio up over +155% avg cumulative return YTD: https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6178504-july-mda-breakout-stocks-week-29-and-highlighted-top-gainers
0 · Reply
biospeculator
biospeculator Jul. 15 at 12:01 PM
$KYTX Cup & handle confirmed. Target equals the bottom of the cup $1.78 to the lip $4 difference of $2.22 + $4. Target is $6.22. However, 5 days of almost 10% moves higher plus the previous move on heavy volume from the low to $4 imo smells like major news coming. Results? Partnerships? Buyout?
0 · Reply
Latest News on KYTX
Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 4:02 PM EDT - 7 weeks ago

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

May 27, 2025, 3:42 PM EDT - 7 weeks ago

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:02 PM EDT - 2 months ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 4:02 PM EDT - 3 months ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Mar 21, 2025, 11:29 AM EDT - 4 months ago

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Mar 3, 2025, 4:05 PM EST - 4 months ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Feb 7, 2025, 11:42 AM EST - 5 months ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

Feb 6, 2025, 1:51 PM EST - 5 months ago

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

Feb 5, 2025, 11:54 AM EST - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

Final Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTX

Feb 4, 2025, 3:51 AM EST - 5 months ago

Final Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTX

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Jan 27, 2025, 3:22 PM EST - 6 months ago

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

Jan 21, 2025, 4:05 PM EST - 6 months ago

Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 7:30 AM EST - 6 months ago

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference

Jan 6, 2025, 4:05 PM EST - 6 months ago

Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference

rsm14il
rsm14il Jul. 16 at 4:51 PM
$ABVX $SLDB $KYTX $UVIX seems like no one is following Abivax. I feel like a small cap foster parent
1 · Reply
mmtiddy
mmtiddy Jul. 16 at 3:58 PM
$KYTX Something is brewing here
0 · Reply
blocktrade
blocktrade Jul. 16 at 2:24 PM
$KYTX weak hands and shorts can 🖕off back over 4🚀
0 · Reply
GSTX7
GSTX7 Jul. 16 at 2:58 AM
$KYTX I traded out on that first dip today. Was up 51% from a couple weeks ago. Second time swing trading with + results. Think the pullback was def sector specific today so I may have left too early. Will hope for another sub-3 entry. Longs are in good shape here. May go long on the next dip if I'm lucky to catch one. Fun stock and a cool company too.
1 · Reply
BluntForceOptions
BluntForceOptions Jul. 15 at 9:40 PM
$KYTX Chart update: We tagged resistance at $4.44 (R-1) before pulling back and closing right at S-1 support ($3.82). After the strong multi-day run from the $2.50 zone, this kind of retracement is normal... even healthy. If we see further downside, I’m watching $3.25 (S-2), which lines up well with the reclaimed trendline that should now serve as support. Still viewing this as digestion, not distribution. Setup’s intact, IMO. Stay tuned.
0 · Reply
ThomasTrainTrader
ThomasTrainTrader Jul. 15 at 7:07 PM
$KYTX healthy pullback for such a huge run, hopefully this stays within the high $3- low $4 range as a temporary floor. This is the most “fair” the valuation has been in ages but it is still an absolute steal below $6, and in a bullish scenario worth close to last years highs around $30
0 · Reply
biospeculator
biospeculator Jul. 15 at 4:38 PM
$KYTX Hopefully a bear raid. Otherwise, pattern has been invalidated. Need this to close above $4.
4 · Reply
blocktrade
blocktrade Jul. 15 at 4:33 PM
$KYTX biotech is getting killed so not surprised considering how much this has moved in the past week.
0 · Reply
AnomalyDetective
AnomalyDetective Jul. 15 at 1:18 PM
As promised, $KYTX first of the Week 29 MDA picks for members up +24.6% from selection in strong breakout conditions with prior Week 28 MDA picks $BTBT +25% $AMPX +51% still going strong at the open today. Simulated weekly MDA portfolio up over +155% avg cumulative return YTD: https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6178504-july-mda-breakout-stocks-week-29-and-highlighted-top-gainers
0 · Reply
biospeculator
biospeculator Jul. 15 at 12:01 PM
$KYTX Cup & handle confirmed. Target equals the bottom of the cup $1.78 to the lip $4 difference of $2.22 + $4. Target is $6.22. However, 5 days of almost 10% moves higher plus the previous move on heavy volume from the low to $4 imo smells like major news coming. Results? Partnerships? Buyout?
0 · Reply
mmtiddy
mmtiddy Jul. 15 at 4:24 AM
$KYTX Give us more, this valuation makes no sense
0 · Reply
rsm14il
rsm14il Jul. 14 at 9:14 PM
$KYTX Some more nuggets for consideration: Gilead owns 9.5% of Kyverna and backed its early financing. CEO of Kyverna came from Kite Pharma. Former CEO of Kite is on Kyverna BOD. Gilead bought Kite for 11.9 billion.
0 · Reply
blocktrade
blocktrade Jul. 14 at 7:38 PM
$KYTX could be the event they are planning to host 3rd qtr. MS analyst believes this will be over the summer.
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jul. 14 at 7:35 PM
$KYTX i admit, i was a buyer a week or so ago in the high twos i also (happily) admit to being out here in the mid 4's more power to all of you continuing to hold this name but the rise was to much too soon for a guy like me watch out for "good" data, which these days can lead to a 35% haircut for a clinical bio such as this one
1 · Reply
blocktrade
blocktrade Jul. 14 at 6:54 PM
$KYTX must be getting near a result. That is the only reason I can think of that is causing this move.
0 · Reply
ThomasTrainTrader
ThomasTrainTrader Jul. 14 at 6:32 PM
$KYTX highs of the year!
0 · Reply
The_Fudster
The_Fudster Jul. 14 at 5:22 PM
$KYTX anything new here? Still holding ~1k shares from low 2s and hadn't watched it closely in a while. Why the recent strength?
1 · Reply
whiskyqueen
whiskyqueen Jul. 14 at 5:15 PM
$KYTX Keep buying here…Not on many radars..Yet.
0 · Reply
rsm14il
rsm14il Jul. 14 at 5:05 PM
$KYTX Excuse my pounding the table here, but this is more than technicals at play. If the trials work out as hoped, we have a single infusion, multi-indication B-cell therapy. That would be a world class drug worth billions of dollars. Admittedly early stage and full of usual biotech risks, but . . .
0 · Reply
intrader
intrader Jul. 14 at 5:03 PM
$KYTX Should see $5.00 or $6.00+ soon.
0 · Reply
rsm14il
rsm14il Jul. 14 at 3:56 PM
$KYTX Asks are thin right now. Seems big buyers are here because the 5-15K share asks get eaten. Whales aren’t going to bother with a couple hundred shares at a time. Patience.
0 · Reply
MarketHounds
MarketHounds Jul. 14 at 2:59 PM
$KYTX patience paid
0 · Reply